Skip to main content

Table 2 Proportions of patients with plasma HIV-1 RNA < 50 copies/mL and < 400 copies/mL at week 48

From: Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study

  Naïve (N = 27) Restart (N = 30) Switch (N = 10) Total (N = 67)
< 50 copies/mL (ITT M = F)     
n/N (%) 7/27 (26) 11/30 (37) 5/10 (50) 23/67 (34)
95% confidence interval1 [11-46] [20-56] [19-81] [23-47]
< 50 copies/mL (ITT M = E)     
n/N (%) 7/16 (44) 11/19 (58) 5/6 (83) 23/41 (56)
95% confidence interval1 [20-70] [34-80] [36-100] [40-72]
< 400 copies/mL (ITT M = F)     
n/N (%) 15/27 (56) 16/30 (53) 6/10 (60) 37/67 (55)
95% confidence interval1 [35-75] [34-72] [26-88] [43-67]
< 400 copies/mL (ITT M = E)     
n/N (%) 15/16 (94) 16/19 (84) 6/6 (100) 37/41 (90)
95% confidence interval1 [70-100] [60-97] [54-100] [77-97]
  1. ITT (M = F) = intent-to-treat missing equals failure analysis; ITT (M = E) = intent-to-treat missing equals excluded analysis
  2. 1Confidence interval on the percentage